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OPEN
ORIGINAL ARTICLE
Genome-wide polygenic scores for age at onset of alcohol
dependence and association with alcohol-related measures
M Kapoor1, Y-L Chou2, HJ Edenberg3, T Foroud3, NG Martin4, PAF Madden2, JC Wang1, S Bertelsen1, L Wetherill3, A Brooks5, G Chan6,
V Hesselbrock6, S Kuperman7, SE Medland4, G Montgomery4, J Tischﬁeld5, JB Whitﬁeld4, LJ Bierut2, AC Heath2, KK Bucholz2,
AM Goate1 and A Agrawal2
Age at onset of alcohol dependence (AO-AD) is a deﬁning feature of multiple drinking typologies. AO-AD is heritable and likely
shares genetic liability with other aspects of alcohol consumption. We examine whether polygenic variation in AO-AD, based on a
genome-wide association study (GWAS), was associated with AO-AD and other aspects of alcohol consumption in two independent
samples. Genetic risk scores (GRS) were created based on AO-AD GWAS results from a discovery sample of 1788 regular drinkers
from extended pedigrees from the Collaborative Study of the Genetics of Alcoholism (COGA). GRS were used to predict AO-AD, AD
and Alcohol dependence symptom count (AD-SX), age at onset of intoxication (AO-I), as well as maxdrinks in regular drinking
participants from two independent samples—the Study of Addictions: Genes and Environment (SAGE; n= 2336) and an Australian
sample (OZ-ALC; n = 5816). GRS for AO-AD from COGA explained a modest but signiﬁcant proportion of the variance in all alcohol-
related phenotypes in SAGE. Despite including effect sizes associated with large numbers of single nucleotide polymorphisms
(SNPs;4110 000), GRS explained, at most, 0.7% of the variance in these alcohol measures in this independent sample. In OZ-ALC,
signiﬁcant but even more modest associations were noted with variance estimates ranging from 0.03 to 0.16%. In conclusion, there
is modest evidence that genetic variation in AO-AD is associated with liability to other aspects of alcohol involvement.
Translational Psychiatry (2016) 6, e761; doi:10.1038/tp.2016.27; published online 22 March 2016
INTRODUCTION
Multiple epidemiological and genetically informed studies have
documented the importance of age at onset of alcohol
dependence (AO-AD) as a key feature of sub-types of alcoholism
that vary in etiology and severity.1–6 For instance, Cloninger et al.3
identiﬁed Type I and II alcoholics who were distinguished by,
among other features, age at onset of alcohol problems. Similarly,
Babor et al.2 deﬁned Type A and B alcoholics—the latter were
distinguished by early onset of alcohol problems. Across these
typologies, early-onset problematic use was consistently asso-
ciated with a more severe form of the disorder, which was often
accompanied by polysubstance use and other psychiatric
comorbidity, particularly externalizing disorders.
AO-AD is also correlated with other features of drinking. For
instance, earlier AO-AD is associated with more alcohol depen-
dence symptoms,2 and this relationship may be inﬂuenced by
shared genetic liability. Cloninger et al.7 also posited that Type
II/early-onset alcoholism may represent a more heritable form of
the disorder. While there have not been studies that examine the
heritability of AO-AD, numerous studies have robustly documen-
ted the role of additive genetic inﬂuences on AD itself8,9 and on
both age at ﬁrst drink10–12 and the speed of transitioning from ﬁrst
use to the development of alcohol problems.13,14 In support of
these ﬁndings, a recent genome-wide association study (GWAS) in
extended pedigrees from the Collaborative Study of the Genetics
of Alcoholism (COGA) found several single nucleotide
polymorphisms (SNPs) that were signiﬁcantly associated with
AO-AD (Po5E− 8).15 For rs2168784, the most signiﬁcant SNP, 30%
of those homozygous for the minor allele met criteria for alcohol
dependence while only 19% of those homozygous for the major
allele did. This SNP was also associated with AD diagnosis in the
COGA dataset.
To our knowledge, none of the top SNP effects identiﬁed in the
previous study by Kapoor et al.15 have yet been replicated.
However, the signiﬁcance associated with individual top SNPs
might be subject to sample-speciﬁc characteristics (for example,
families densely affected for alcoholism). Recently, investigators
have begun to use genome-wide risk scores (GRS) that reﬂect the
polygenic and aggregate nature of genotypic effects. Effect sizes
generated for one phenotype in a given sample can be used to
generate GRS in additional samples; the association between
these GRS and a similar phenotype may be seen as evidence for
replication while correlations between the GRS and other related
phenotypes provide support for shared genetic underpinnings.16
The present study utilizes GRS generated from the analysis of
AO-AD in COGA (discovery sample) conducted by Kapoor et al.15
and applies these scores to two independent samples, the Study
of Addictions Genes and Environment (SAGE; using the portion
independent of the COGA subjects who were in the discovery
sample)17 and a sample of Australian subjects (OZ-ALC).18 In
contrast to COGA, which is comprised of extended pedigrees with
a high rates of alcohol dependence, SAGE consisted of alcohol-
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dependent cases and alcohol exposed but non-dependent
controls. Even though SAGE subjects were drawn from studies
that used family history of alcohol and drug dependence to
ascertain cases, including COGA, all overlapping subjects were
removed and all subjects were unrelated to each other. OZ-ALC,
on the other hand, consisted of pedigrees that were derived from
various sources, including family studies ascertained for heavy
drinking and heavy smoking and a sample consisting of large
sibships. Despite being similar to COGA for sibship size, the
density of alcohol-related problems in the OZ-ALC pedigrees is
substantially lower. The variability in SAGE and OZ-ALC allowed us
to investigate the generalizability of the COGA ﬁndings.
Overall, we were interested in replicating and generalizing our
prior ﬁndings and extending them to other alcohol-related
phenotypes. Thus, our goals were twofold: ﬁrst, we examine
whether GRS created from the GWAS of AO-AD in the COGA
discovery sample15 is associated with AO-AD in the independent
portion of SAGE and in OZ-ALC. Second, we examine whether GRS
for AO-AD is associated with other features of alcohol involve-
ment, including age at ﬁrst intoxication, lifetime maximum drinks
in a 24-h period and number of symptoms and diagnosis of
alcohol dependence in the SAGE and OZ-ALC datasets.
MATERIALS AND METHODS
Sample
Data were drawn from the three sources described below. The institutional
review board at each contributing institution reviewed and approved the
protocols.
Discovery sample
The discovery sample was genome-wide SNP data on 1788 regular drinkers
(deﬁned below) from 118 large European-American families densely
affected with alcoholism;15 subjects from that study who were not regular
drinkers were excluded. Ascertainment was based on a proband in
treatment for alcohol dependence who had at least two ﬁrst-degree
relatives affected by alcohol dependence. Of these subjects, 685 met
criteria for DSM-IV alcohol dependence (mean age of onset 22.5 years). A
genome-wide Cox proportional hazards regression model was used to test
the association between age at onset of AD and 4 058 415 imputed SNPs
with minor allele frequency ⩾ 5%.15 A robust sandwich variance estimators
approach was used to account for the familial correlation among
observations (https://cran.r-project.org/web/packages/survival/survival.pdf).
Replication samples
SAGE consisted of 2593 unrelated European-American subjects. Of these,
2336 individuals who reported regular drinking were included in these
analyses. Subjects were selected from three large, complementary studies:
COGA,19 Family Study of Cocaine Dependence (FSCD)20 and Collaborative
Genetic Study of Nicotine Dependence (COGEND).21 Further details of the
SAGE sample are available elsewhere.17 One hundred and twenty nine
individuals who were both in SAGE and the COGA discovery sample were
excluded. The sample consisted of alcohol-dependent cases (N= 1167,
mean age at onset 24.7 years) and alcohol-exposed controls (N= 1169).
The OZ-ALC sample consisted of 6169 individuals (for this study, 5816
regular drinkers were included) from 2356 families ascertained from 3
coordinated studies derived from a larger Australian twin registry: (i) the
Nicotine Addiction Genetics (NAG) Study which ascertained heavy smoking
index cases; (ii) the OZ-ALC-EDAC study, which ascertained index cases
with a history of alcohol dependence or scoring above the 85th centile for
heaviness of drinking factor score (operationalized as in the study by Grant
et al.22); (iii) the OZ-ALC-BIGSIB study, which ascertained large sibships
(4–14 full siblings), regardless of sibling phenotypes. Further details
regarding recruitment may be found in the study by Heath et al.18 OZ-ALC
was not ascertained for alcohol dependence (although some contributing
studies were ascertained for heavy smoking and heavy alcohol consump-
tion) and includes 1714 alcohol-dependent individuals (mean age of onset
26.3 years).
Phenotypic assessments
The discovery and replication samples utilized versions of the Semi-
Structured Assessment for the Genetics of Alcoholism (SSAGA)23,24 to
obtain interview-based self-report data on ages of onset and other alcohol-
related measures. In the discovery sample, AO-AD was deﬁned as the age
at which individuals reported ﬁrst experiencing three or more of seven
DSM-IV alcohol dependence criteria clustering within a 12-month period.
Only individuals who were regular drinkers (that is, reported a lifetime
history of drinking at least once a month for 6 months or longer) were
included. As is the norm for Cox survival modeling, those who did not
meet criteria for DSM-IV AD were censored at their age at interview.
For the present analyses, in addition to AO-AD, which was coded
identically as in the discovery sample, the following measures were drawn
from SAGE and OZ-ALC:
Alcohol-related measures
AO-I, deﬁned as the age at which the respondent reported ﬁrst getting
drunk (that is, their speech was slurred or they felt unsteady on their feet).
AD diagnosis (binary) was based on DSM-IV; individuals who endorsed
three or more criteria that clustered within a single 12-month period were
diagnosed with AD.
Alcohol dependence symptom count (AD-SX) was deﬁned as the sum of
the seven DSM-IV dependence criteria.
Maxdrinks, deﬁned as the maximum number of drinks consumed in a
single 24-h period during their lifetime. The measure was Winsorized at the
95th percentile (4100 drinks) and log (10) transformed for analyses.
Negative control
Height, via self-report, was used as a negative control.
Genotyping in discovery sample
Genotyping was conducted using the Illumina OmniExpress array (Illumina,
San Diego, CA, USA). A total of 4 058 415 SNPs that were imputed in
BEAGLE (https://faculty.washington.edu/browning/beagle/beagle.html)
were analyzed. Further details are available in the manuscript by Kapoor
et al.;15 data are available at dbGaP phs000763.
Genotyping in replication samples
For SAGE, DNAs were genotyped on the Illumina Human 1 M beadchip
(Illumina) by the Center for Inherited Diseases Research (CIDR) at the Johns
Hopkins University; data are available at dbGaP phs000092. A total of
948 658 SNPs passed data-cleaning procedures and further within sample
ﬁltering for autosomal and X-chromosome markers yielded 948 142
markers. HapMap genotyping controls, duplicates, related subjects and
outliers were removed from the sample set.17 The software package
EIGENSTRAT25 was used to calculate principal components reﬂecting
ancestral differences. Only genotyped SNPs were selected from SAGE,
resulting in 669 984 overlapping SNPs which were further pruned for
linkage disequilibrium (maximum pairwise r2 = 0.25 within sliding windows
of 100 SNPs), resulting in 90 365 SNPs that were used for all subsequent
analyses.
For OZ-ALC, most subjects (N= 4601) were genotyped on the Illumina
CNV370-Quadv3 (Illumina); genotyping on a small number of additional
individuals was conducted on the Illumina 317 K (N= 20) and 610 Quad v1
(N= 517) platforms; data are available at dbGaP phs000181 (see the
study by Medland et al.,26 for additional details). To account for the lower
density of genotyped SNPs and variation in platform contents, imputation
to HapMap (http://hapmap.ncbi.nlm.nih.gov) CEU I+II data (release 22,
build 36) was conducted in MACH27 and best guess genotypes were
selected based on Rsq⩾ 0.3 and imputation quality⩾ 0.9, resulting in
112 594 autosomal SNPs. Nuanced admixture was determined using
EIGENSTRAT25 and outliers were removed, as outlined in the study by
Heath et al.18
Association using GRS in replication datasets
Based on effect sizes for the analysis of AO-AD generated in the discovery
(COGA) sample, GRS at P-value thresholds of 0.01 (GRS0.01), 0.05 (GRS0.05),
0.10 (GRS0.1) and 0.50 (GRS0.5) were created in SAGE and OZ-ALC sample
using PLINK28 and SAS (SAS Institute, Cary, NC, USA). Brieﬂy, SNPs in COGA
that were signiﬁcant at each P-value threshold (for example, Po0.01) were
selected. For each SNP, the effect size was calculated as the natural
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logarithm transformation of the hazard ratio from COGA. For every
individual in SAGE and OZ-ALC, this effect size was multiplied by the
number of copies of reference allele, and this product was summed across
all SNPs.28 For the SAGE dataset, the number of SNPs for each score was:
GRSall (110 797), GRS0.5 (58 374), GRS0.1 (12 254), GRS0.05 (6147) and GRS0.01
(1441), while for OZ-ALC number of SNPs for each score was: GPSall
(112 594), GPS0.5 (57 053), GPS0.1 (12 161), GPS0.05 (6268) and GPS0.01
(1402). The resulting GRS was used to predict AO-AD, as well as other
Table 1. Characteristics of 2593 European-American subjects, stratiﬁed by diagnosis of DSM-IV AD in the regular alcohol drinkers in the replication




















Males (%) 1089 (46.6) 710 (60.8) 379 (32.4) 2825 (48.6) 1074 (62.7) 1751 (42.7)
Age at Interview (mean± sd) 38.2± 9.5 38.2± 9.9 38.3± 9.1 44.3± 9.3 41.1± 8.1 45.61± 9.4
Alcohol-related measures
Ever got drunk (%) 2274 (97.4) 1167 (100) 1107 (94.7) 5411 (98.9) 1708 (99.7) 3703 (98.35)
AO-I (mean± sd) 17.2± 6.6 15.2± 3.5a 19.3± 8.1a 18.3± 5.6 16.4± 2.9a 19.1± 6.3a
Maxdrinks 20.9± 19.2 30.3± 20.7a 11.5 ± 11.5a 18.4± 14.1 26.8± 15.5a 14.9± 11.8a
AD-SX 3.1± 2.5 5.3± 1.5a 0.9± 0.9a 1.9± 1.7 4.0± 1.2a 1.0± 1.0a
AO-AD (mean± sd) — 24.7± 7.7 — — 26.3± 8.6 —
Control measure
Height (in) 67.6+3.9 68.4+3.8a 66.9+3.8a 67.5± 3.9 68.4± 3.8a 67.1± 3.9a
Abbreviations: AD, alcohol dependence; AD-SX, total number of DSM4 AD symptoms endorsed; AO-AD, age at onset of AD; AO-I, age at onset of intoxication;
DSM-IV, Diagnostic and Statistical Manual IV; Maxdrinks, maximum number of alcoholic drinks in 24 h; SAGE, Study of Addictions: Genes and Environment .
aStudent t-test, Po0.0001.
Table 2. GRS generated from an analysis of AO-AD in a discovery sample, at varying P-value thresholds, predicting AO-AD, other features of drinking
in regular drinkers from SAGE (N= 2336) and OZ-ALC (N= 5816)
Age of onset measures Binary measure
AO-AD AO-I AD
SAGE OZ-ALC SAGE OZ-ALC SAGE OZ-ALC
P-value Adj. R2 (%) P-value Adj. R2 (%) P-value Adj. R2 (%) P-value Adj. R2 (%) P-value Adj. R2 (%) P-value Adj. R2 (%)
GRSall 9.90E− 05 0.5 4.23E− 02 0.06 1.33E− 02 0.2 2.14E− 02 0.08 7.98E− 05 0.5 2.69E− 02 0.05
GRS0.5 6.70E− 06 0.7 3.03E− 02 0.07 6.42E− 03 0.3 2.60E− 02 0.07 5.26E− 06 0.6 2.03E− 02 0.06
GRS0.1 1.95E− 03 0.3 1.09E− 01 0.03 4.71E− 03 0.3 2.87E− 02 0.06 6.88E− 04 0.4 4.88E− 02 0.03
GRS0.05 5.96E− 02 0.1 4.88E− 02 0.05 2.58E− 02 0.2 1.17E− 02 0.08 6.96E− 02 0.1 4.82E− 02 0.04
GRS0.01 2.96E− 01 0.1 8.52E− 01 0.00 3.70E− 01 0 1.86E− 01 0.00 2.96E− 01 0 6.52E− 01 0.00
AD-SX LOG10 Maxdrinks (Maxdrinks) Height (negative control)
SAGE OZ-ALC SAGE OZ-ALC SAGE OZ-ALC
P-value Adj. R2 (%) P-value Adj. R2 (%) P-value Adj. R2 (%) P-value Adj. R2 (%) P-value Adj. R2 (%) P-value Adj. R2 (%)
Quantitative measures
GRSall 3.54E− 05 0.6 2.41E− 03 0.13 7.97E− 05 0.5 2.52E− 02 0.05 9.54E− 02 0 7.93E− 01 0.00
GRS0.5 2.07E− 06 0.8 2.51E− 03 0.12 9.56E− 07 0.7 1.59E− 02 0.05 1.09E− 01 0 8.53E− 01 0.00
GRS0.1 6.40E− 05 0.6 1.93E− 03 0.16 1.13E− 04 0.4 1.38E− 02 0.05 9.92E− 01 0 4.68E− 01 0.00
GRS0.05 6.53E− 03 0.2 3.59E− 03 0.09 5.13E− 03 0.2 3.77E− 02 0.004 8.49E− 01 0 9.43E− 01 0.00
GRS0.01 6.95E− 02 0.1 1.06E− 01 0.03 2.58E− 02 0.1 8.90E− 01 0.00 5.18E− 01 0 9.68E− 01 0.01
Abbreviations: AD, alcohol dependence; AD-SX, total number of DSM4 AD symptoms endorsed; AO-AD, age at onset of AD; AO-I, age at onset of intoxication;
GRS, genome-wide polygenic scores; SAGE, Study of Addictions: Genes and Environment; SNP, single nucleotide polymorphism. For SAGE, numbers of SNPs
for each score were as follows: GRSall (110 797), GRS0.5 (58 374), GRS0.1 (12 254), GRS0.05 (6147) and GRS0.01 (1441). For OZ-ALC: GPSall (112 594), GPS0.5 (57 053),
GPS0.1 (12 161), GPS0.05 (6268) and GPS0.01 (1402). The analysis was rerun after removing the MHC region (chr6:28 477 796–33 448 353). There was no change
in the adjusted R2, while P-values ﬂuctuated slightly due to small change in number of SNPs.
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measures (AO-R, AO-I, AD-SX and Maxdrinks) in those datasets. Associa-
tions between age of onset measures and GRS were conducted using Cox
proportional hazards analysis. Logistic and linear regression was used for
dichotomous (AD) and continuously distributed (AD-SX, Maxdrinks)
measures, respectively. Similar to the analysis in the discovery sample, a
robust sandwich variance estimator approach was used to account for the
familial correlation among OZ-ALC families. For both studies, sex, age at
last interview and study source (COGEND vs FSCD vs COGA; NAG vs EDAC
vs BIGSIB) were included as covariates.
Sensitivity analysis
Based on recommendations by Dudbridge,29 that replication of polygenic
scores is optimized when the size of the discovery and test samples is
approximately equal; we performed 10 000 iterations in which we
randomly resampled 1788 individuals from the pool of 2336 subjects in
SAGE. Cox proportional hazard models were ﬁt to each randomly drawn
sample to examine whether the magnitude of the association was
modiﬁed by selection of a comparatively sized test sample. Similar
analyses were not conducted in OZ-ALC as random selection of subsets of
individuals nested in pedigrees would not be representative of the
sampling design nor would selection of subsets of whole pedigrees allow
for adequate numbers of individuals with AO-AD.
RESULTS
Sample characteristics
Characteristics of the replication samples, SAGE and OZ-ALC, are
presented in Table 1. In both samples, those meeting criteria for
AD (NSAGE = 1167; NOZ-ALC = 1714) were more likely to report an
earlier AO-I. They also reported higher Maxdrinks. In general,
individuals from SAGE were heavier drinkers and have a greater
number of AD-SX than those from OZ-ALC. This is unsurprising
given the differences in ascertainment strategies. Modestly, earlier
onset of drinking to intoxication and AD was noted in SAGE
relative to OZ-ALC. No differences in height were noted across
individuals with and without AD or across SAGE and OZ-ALC.
Association between GRS and alcohol measures
As shown in Table 2 and Figure 1, GRS for AO-AD were
signiﬁcantly associated with AO-AD and also with AD in SAGE
for cutoffs above GRS0.05. Increasing P-value thresholds resulted in
greater proportion of variance explained with the adjusted R2
ranging from 0.3% for GRS0.1 to 0.7% for GRS0.5. The variance
explained was maximum when we included the SNPs with P⩽ 0.5.
In addition to AO-AD, GRS explained a modest proportion of the
variance in AO-I (≈0.3%). GRS from COGA were also related to AD-
SX and Maxdrinks in SAGE, explaining 0.2 to 0.8% of the variance
in these measures.
In contrast, AO-AD GRS from COGA explained only a very
modest (but signiﬁcant) proportion of variation in AO-AD (0.06–
0.07%) and AD (0.03–-0.06%) in OZ-ALC (Table 2 and Figure 2). The
GRS were modestly associated with AO-I (0.2–0.3%), as well as
with AD-SX (0.09–0.13%) and Maxdrinks (0.004–0.05%) in OZ-ALC.
The associations were far less signiﬁcant than those noted in
SAGE, explaining ⩽ 0.16% of the variance in alcohol-related
phenotypes. Height was included as a negative control and was
not associated (P40.05) with any GRS across SAGE and OZ-ALC.
Resampling 10 000 subsets of SAGE individuals to create a
sample size that was equivalent to COGA resulted in similar
results. GRS showed statistically signiﬁcant association with the
Figure 1. GRS generated from an analysis of AO-AD in a discovery sample, at varying P-value thresholds, predicting (a) AO-AD, (b) AO-I, (c ) AD,
(d) AD-SX, (e) Maxdrinks and (f) height in SAGE dataset. The x-axis represents the GRS thresholds and y-axis represents the adjusted R2 for the
trait. Each bar represents the values of adjusted R2 for SAGE. Colors of the bar represent the level of signiﬁcance achieved. AD, alcohol
dependence; AD-SX, total number of DSM4 AD symptoms endorsed; AO-AD, age at onset of AD; AO-I, age at onset of intoxication; GRS,
genome-wide polygenic scores; SAGE, Study of Addictions: Genes and Environment.
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AO-AD (Po0.05) in the reduced SAGE dataset in all 10 000
permutations. However, the reduction in sample size inﬂuenced
the magnitude of P-values and only about 12% of the time, the
association P-values were equal to or more signiﬁcant than the
original P= 6.70 × 10− 06 observed with the full SAGE sample.
DISCUSSION
Using effect sizes generated via a prior GWAS of AO-AD in the
COGA family sample,15 we created GRS at varying P-value
thresholds and examined their association with AO-AD, AD, AO-I,
as well as liability to problematic drinking (AD-SX and Maxdrinks)
in two independent and differently structured and ascertained
datasets, SAGE and OZ-ALC. GRS, especially when including SNPs
associated with AO-AD at more liberal P-value thresholds, were
signiﬁcantly associated with a range of these alcohol-related
measures in those two independent and distinctly ascertained
samples. In contrast, there was no evidence for replication of the
top 10 most signiﬁcantly associated variants from COGA in either
SAGE (6.6 × 10− 1–8.1 × 10− 1) or OZ-ALC (8.7 × 10− 1–8.9 × 10− 1).
This strongly underscores the idea that multiple common genetic
effects contribute to the etiology of complex disorders like
addictions.
GRS comprised of 4110 000 SNPs only captured very modest
proportions of the variance in any alcohol-related measure
(o1%). This observation is consistent with other studies.30–32
For instance, Vink et al.32 used GRS constructed from a large meta-
analysis of GWAS of tobacco smoking measures to predict
variance in alcohol, tobacco and cannabis-related outcomes. In
that study, polygenic scores that were associated with tobacco-
related measures at Po10− 70 explained, at most, 1.5% of the
variance in any substance-related outcome. Similarly, Power
et al.30 examined the relationship between cannabis involvement
and GRS generated from a meta-analysis of schizophrenia
(N= 13 833 cases, 18 310 controls) which included 13 genome-
wide signiﬁcant loci. Even though schizophrenia GRS were
signiﬁcantly associated with cannabis use, the scores, even at
Po0.05 explained o1% of the variance in cannabis-related
phenotypes. For alcohol-related measures, Salvatore et al.31 found
that GRS generated for alcohol problems (N= 4304) only predicted
0.6% of the variance in a similar measure in an independent
sample. Despite relying on a smaller discovery sample (COGA,
N= 1788), our ﬁndings are consistent with these estimates.
Nonetheless, the small sample size of the discovery set limits
the accuracy of predicted SNP effect sizes and likely inﬂuenced
our ability to generate GRS that might be reliable predictors of
alcohol involvement in independent samples.
An additional consideration when viewing these results is the
difference in ascertainment method across COGA, SAGE and OZ-
ALC. The discovery sample (COGA) consisted of extended
pedigrees ascertained for a dense family history of alcoholism
and it was not expected that all variants associated with alcohol-
related measures in such densely affected pedigrees would
generalize to other cohorts. SAGE cases were selected for DSM-
IV alcohol dependence from among several studies focused on
alcohol, tobacco and cocaine and thus, as expected, we note a
stronger degree of replication in this sample. In contrast, OZ-ALC
comprises of samples ascertained for heavy smoking, discordance
of heavy alcohol consumption measures and also for large sibship
size (without any oversampling for substance-related phenotypes).
Figure 2. GRS generated from an analysis of AO-AD in a discovery sample, at varying P-value thresholds, predicting (a) AO-AD, (b) AO-I, (c ) AD,
(d) AD-SX, (e) Maxdrinks and (f) height in OZ-ALC dataset. The x-axis represents the GRS thresholds and y-axis represents the adjusted R2 for
the trait. Each bar represents the values of adjusted R2 for OZ-ALC. Colors of the bar represent the signiﬁcance level achieved. AD, alcohol
dependence; AD-SX, total number of DSM4 AD symptoms endorsed; AO-AD, age at onset of AD; AO-I, age at onset of intoxication; GRS,
genome-wide polygenic scores.
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Therefore, it is not surprising that replication in OZ-ALC, a less
severely affected sample, is weaker for AO-AD, but occurs for ages
of onset for earlier drinking milestones (for example, AO-I) and for
measures that are quantitative indices of problem drinking (for
example, AD-SX). In OZ-ALC, AO-I and AO-R, as well as AD-SX and
Maxdrinks may serve as proxies for genetic liability to problematic
drinking, while in COGA and SAGE this liability may be
appropriately captured by AO-AD itself. Even so, the statistical
signiﬁcance of the associations and the proportions of variance
explained in OZ-ALC are markedly lower than those in SAGE.
Nonetheless, as OZ-ALC is so markedly distinct from COGA and
SAGE, any level of association between COGA GRS and alcohol-
related measures in OZ-ALC may be considered as support for the
generalizability of the COGA results.
Dudbridge et al.29 has noted that there are two purposes for
GRS: association testing (that is, replication, reliant on signiﬁcance/
P-value) and prediction of phenotypic variance (for example,
reliant on R2 estimates). Based on numerous simulations, he
concluded that while most studies with approximately equally
sized training (that is, COGA) and testing (for example, SAGE)
samples are well-powered for association testing, current training
samples are underpowered for prediction. Consistent with this
observation, we were interested in the former rather than the
latter and even though we report R2 values, the emphasis of our
analysis was association testing. We conﬁrm that selecting a
testing sample of approximately the same size as the training
cohort, as was achieved via our bootstrapping approach, yields
signiﬁcant association. Dudbridge29 notes that 10-fold cross-
validation might be a more efﬁcient approach to maximizing
prediction. As two of our samples are family-based (COGA and OZ-
ALC), such cross-validation approaches, which may necessitate
disaggregating members of pedigrees or selecting subsets of
pedigrees that may or may not be informative for the etiology of
genetically transmitted AD, may not be applicable. Hence, our
ﬁndings should be observed in the context of association (and not
prediction) testing alone.
Finally, it is worth noting that we did not attempt to
characterize the SNPs that comprised each GRS nor did we create
biologically informed GRS by selecting variants that related to a
speciﬁc neurotransmitter pathway (for example, dopamine variant
proﬁle). Given the high false discovery rates typically associated
with ascribing a functional direction to such variants of purported
biological importance (except, perhaps, the alcohol dehydrogen-
ase variants) and our currently limited understanding of the
etiology of AD, we employed a more conservative and agnostic
approach of utilizing genome-wide data. Future studies that
contrast such genome-wide PRS with biologically informed risk
scores may be valuable in the construction of the architecture
underlying the polygenicity associated with complex traits such as
AO-AD. Nonetheless, our approach precludes any mechanistic
interpretation of the polygenicity represented by each GRS.
In conclusion, using GRS generated for AO-AD, we document
that similar genetic factors might underpin the liability to alcohol
dependence, drinking to intoxication and indices of problematic
drinking in independent datasets. Future studies could strengthen
these interpretations by conducting meta-analyses across multiple
samples to produce larger discovery samples for generating GRS
that could be applied to a wider range of alcohol and other
substance phenotypes.
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